Results from The Zitter Group’s Recent Oncology Survey Presented in December 1 Webinar

Share Article

The Zitter Group’s director of access strategies will discuss the results of her firm’s most recent oncology surveys — and share strategies payers are using to manage the soaring costs of oncology treatments — in this Dec. 1 webinar presented by AIS.

Atlantic Information Services, Inc., publisher of Specialty Pharmacy News, Drug Benefit News and Health Plan Week, is pleased to announce its December 1 webinar, Payer and Physician Oncology Management Trends: Survey Results From The Zitter Group. See webinar details at

Oncology drugs continue to be a growing driver of specialty drug spending and overall pharmacy spending as well. But most health plans are new to the management of these therapies, as they traditionally have given oncologists carte blanche to treat patients. Information on what payers are spending in this area, though, is hard to come by, because many of these therapies are physician-administered and fall under the medical benefit, and treatment regimens may change often. With hundreds of oncology drugs in the pharmaceutical pipeline, health plans need to identify and adopt effective management strategies … and understand the oncologist perspectives on those tactics as well. The stakes are enormous for payers to get the best possible outcomes for patients and their own bottom lines.

This webinar will be presented by Melinda Haren, RN, The Zitter Group’s director of access strategies, who will discuss the results of her firm’s most recent oncology surveys. One survey reflects the views of 100 payers, 100 oncologists and 100 oncology practice managers, and the other is based on a database that houses the prior-authorization data and/or policies of approximately 175 leading commercial health plans, 65 Medicare plans and 135 managed and state Medicaid plans.

During the 60-minute presentation and 30 minutes of Q&A, webinar attendees will get valuable perspectives on:

  • What are the latest payer oncology management policies and philosophies?
  • What kinds of prior-authorization tactics are payers using? What results are they achieving?
  • What is the difference between “preferred” and “favored” agents, and what are payers doing in this area?
  • What approaches are payers using to limit the use of some therapies? Which therapies are they applied to most often?
  • How do payers and oncologists view the impact of accountable care organizations on oncology versus other therapeutic areas?
  • What reimbursement methodologies and percentages are payers applying to oncology drugs?
  • What types of new joint efforts are under way between payers and oncologists? What results are they achieving?

Visit for more details and registration information.

About AIS
AIS develops highly targeted news, data and strategies for managers in hospitals, health plans, medical group practices, pharmaceutical companies and other health care organizations. Learn more at

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Shelly Beaird-Francois
Visit website